FINWIRES · TerminalLIVE
FINWIRES

CARsgen Therapeutics Gets Nod for Gastric Cancer Drug Application in China

By

CARsgen Therapeutics (HKG:2171) obtained approval for the new drug application of satricabtagene autoleucel from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.

The drug was approved for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma.

Related Articles